Scholarlink

<p>Prostate cancer (PCa) is a prevalent male cancer with high survival rates, except in advanced or metastatic stages, for which effective treatments are lacking. Metastatic PCa involves complex mechanisms including loss of tumor suppressor genes and DNA repair molecules, which impacts therapy responses. Analyses of tumor samples demonstrated that <i>SYCP3</i> expression is frequently upregulated in PCa tumors from patients in advanced stages. Due to the implication of <i>SYCP3</i> on DNA repair processes, we have analyzed the role of <i>SYCP3</i> on the cellular response to radiotherapy (RT) and found that its depletion induced RT resistance, suggesting a role for <i>SYCP3</i> in DNA damage response and genomic instability. Additionally, based on a previous CRISPR/Cas9 genome-wide screening identifying SYCP3 as a potential regulator of metastatic invasion in DU145 PCa cells, we performed biological validation analyses, which showed that SYCP3 depletion significantly reduced the invasive and migratory abilities of DU145 cells and increased their adhesion capacity. All these data support a role for <i>SYCP3</i> in PCa metastasis and provides opportunities for personalized medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SYCP3 enhances prostate cancer metastasis and modulates the DNA damage response pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Maria Rodrigo-Faus,
  • Ines del Monte-Garcia,
  • Marina Hermosilla-Trespaderne,
  • Alicia Gordo-Vega,
  • Natalia Vidal,
  • Javier Puente,
  • Melchor Saiz-Pardo,
  • Ángel M. Cuesta,
  • Hui-Qi Qu,
  • Hakon Hakonarson,
  • Almudena Porras,
  • Daniel Sanchez-Parcerisa,
  • Paloma Bragado,
  • Alvaro Gutierrez-Uzquiza

摘要

Prostate cancer (PCa) is a prevalent male cancer with high survival rates, except in advanced or metastatic stages, for which effective treatments are lacking. Metastatic PCa involves complex mechanisms including loss of tumor suppressor genes and DNA repair molecules, which impacts therapy responses. Analyses of tumor samples demonstrated that SYCP3 expression is frequently upregulated in PCa tumors from patients in advanced stages. Due to the implication of SYCP3 on DNA repair processes, we have analyzed the role of SYCP3 on the cellular response to radiotherapy (RT) and found that its depletion induced RT resistance, suggesting a role for SYCP3 in DNA damage response and genomic instability. Additionally, based on a previous CRISPR/Cas9 genome-wide screening identifying SYCP3 as a potential regulator of metastatic invasion in DU145 PCa cells, we performed biological validation analyses, which showed that SYCP3 depletion significantly reduced the invasive and migratory abilities of DU145 cells and increased their adhesion capacity. All these data support a role for SYCP3 in PCa metastasis and provides opportunities for personalized medicine.